Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Other Non Operating Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Non Operating Income for 4 consecutive years, with $103000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 2.83% to $103000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $275000.0 through Dec 2025, down 22.54% year-over-year, with the annual reading at $275000.0 for FY2025, 22.32% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $103000.0 at Century Therapeutics, up from $97000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $4.4 million in Q4 2022, with the low at -$194000.0 in Q1 2023.
  • Average Other Non Operating Income over 4 years is $307500.0, with a median of $11500.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income tumbled 3820.0% in 2023, then surged 1983.33% in 2024.
  • Over 4 years, Other Non Operating Income stood at $4.4 million in 2022, then crashed by 100.34% to -$15000.0 in 2023, then skyrocketed by 806.67% to $106000.0 in 2024, then fell by 2.83% to $103000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $103000.0, $97000.0, and $113000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.